Saturday, March 15, 2025
4.4 C
London
HomeFinTechPharmAust: Begins recruiting dogs for canine cancer trial

PharmAust: Begins recruiting dogs for canine cancer trial

Date:

ABN AMRO-Owned Neobroker Fined $1.6M for Paying Finfluencers

A Significant Penalty in the Financial Industry Highlights Regulatory...

AvidXchange Explores Potential Sale Amid Market Changes

What Investors Need to Know About AvidXchange's Strategic ShiftHighlights:...

Raisin Expands Its Offerings by Launching in Finland

Discover how Raisin is transforming the financial landscape in...
  • PharmAust (PAA) has officially started recruiting patients for a second-phase clinical trial testing one of its key drugs against cancer in dogs
  • The phase IIb trial will test PharmAust’s monepantel (MPL) treatment against naive B-cell lymphoma in dogs
  • This is one of the most common types of cancer in dogs, accounting for around 20 per cent of all canine cancers
  • PharmAust has started treating eligible dogs with MPL under the trial and also started giving six dogs not eligible for the trial compassionate treatment
  • The company says the overall market for veterinary medicinal products is more than $22 billion
  • Shares in PharmAust closed grey this afternoon at 10 cents each

Related stories

spot_img

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories